By William Collins, consultant in stock markets – Eurasia Business News, August 19, 2026. Article no 4005
Moderna shares nearly doubled on August 19 after the biotechnology company and Merck announced positive Phase 3 results for their personalised mRNA cancer vaccine in high-risk melanoma patients. The breakthrough represents the first successful late-stage study of an mRNA-based cancer therapy and could open a major new chapter for personalised oncology treatment.
The experimental treatment, intismeran autogene—also known as V940 or mRNA-4157—is being developed in combination with Merck’s blockbuster immunotherapy Keytruda. The vaccine is designed to train a patient’s immune system to recognise unique mutations, or neoantigens, associated with their individual tumour.
Phase 3 Melanoma Results
The global Phase 3 INTerpath-001 trial enrolled 1,137 patients with high-risk stage IIB to IV cutaneous melanoma whose tumours had been completely removed through surgery. Participants received either the personalised mRNA vaccine plus Keytruda or Keytruda alone, the current standard of care in the adjuvant setting.
At a pre-specified interim analysis, the combination met the study’s primary endpoint of recurrence-free survival. It also achieved a key secondary endpoint of distant metastasis-free survival, meaning it reduced the risk of melanoma returning or spreading to distant parts of the body compared with Keytruda alone. The companies described the results as statistically significant and clinically meaningful.
No new safety signals were identified, according to the trial announcement. The study will continue to assess overall survival, a critical endpoint that measures whether the treatment helps patients live longer. Detailed efficacy data have not yet been released.
Why Moderna Stock Rose
The results validate years of research into using messenger RNA technology beyond infectious-disease vaccines. Moderna became widely known for its COVID-19 vaccine, but falling pandemic-vaccine sales had increased pressure on the company to prove the commercial value of its broader pipeline.
Read also : Tax Management strategies for Digital Nomads
A positive Phase 3 cancer-vaccine result provides a potentially transformative opportunity. The therapy’s personalised design could support premium pricing, although manufacturing, reimbursement, regulatory review and long-term survival data will be important considerations before any commercial launch.
William Blair upgraded Moderna from “Market Perform” to “Outperform” following the announcement. Moderna Chief Executive Stéphane Bancel said the therapy could potentially receive regulatory approval as early as 2027, subject to review by health authorities.
Biotech Stocks Gain
The Moderna and Merck news lifted sentiment across the biotechnology sector. BioNTech, Moderna’s German mRNA peer, traded higher after the results, while Novavax also advanced. The SPDR S&P Biotech ETF, which tracks a broad group of biotechnology companies, rose more than 4%, putting it on course for its strongest intraday gain since March.
Read also : The Million-Dollar Retirement Blueprint for U.S. citizens in 2026
For investors, the mRNA cancer vaccine trial is a major scientific and market milestone. However, intismeran remains investigational, and its ultimate value will depend on full trial data, overall-survival outcomes, regulatory decisions and the ability of Moderna and Merck to scale personalised vaccine production.
Our community already has nearly 325,000 readers!
Subscribe to our Telegram channel
Follow us on Telegram, Facebook and Twitter
© Copyright 2026 – Eurasia Business News. Article no. 4005
Eurasia Business News 